Category - Markets

Ladenburg Thalmann launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $11.25 price target. The stock closed at $6.95 on March 11. “We view Cidara as a balanced portfolio of infectious disease...

William Blair launched coverage of Akari Therapeutics (NASDAQ:AKTX) with an “outperform” rating. The stock closed at $11.62 on April 5. Akari is focused on the development of next-generation complement inhibitors for...

H.C. Wainwright raised its price target for SteadyMed (NASDAQ:STDY) to $15 from $10 after the Patent Trial and Appeal Board ruled in favor of SteadyMed in an inter partes review (IPR) proceeding against United...

Leerink resumed coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating and a $16 price target, saying the company is well positioned to execute with multiple sources of upside. The stock closed at...

H.C. Wainwright upgraded Galectin Therapeutics (NASDAQ:GALT) to “buy” from “neutral” and raised its price target to $3 from 60 cents, citing a more positive view of the therapeutic potential of the mechanism of galectin...

H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on...

H.C. Wainwright raised its price target for Verastem (NASDAQ:STM) to $6.50 from $5, ahead of a highly anticipated top-line readout from the Phase 3 DUO study of duvelisib for the treatment of relapsed/refractory chronic...

Vital Therapies (NASDAQ:VTL) has priced a public offering of 8,750,000 newly issued common shares at a price of $4 each for gross proceeds of approximately $35-million. Vital also granted the underwriters a 30-day...

Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21. CKPT focuses on combination treatments for solid tumors based...

Oppenheimer & Co., a unit of Oppenheimer Holdings (NYSE:OPY), has hired a new life sciences team, led by Michael Margolis, to join the firm’s healthcare investment banking group. Mr. Margolis will serve as...